China SXT Pharmaceuticals (SXTC) Equity Ratio (2018 - 2025)
China SXT Pharmaceuticals (SXTC) has 8 years of Equity Ratio data on record, last reported at 0.71 in Q1 2025.
- For Q1 2025, Equity Ratio rose 18.32% year-over-year to 0.71; the TTM value through Mar 2025 reached 0.71, up 18.32%, while the annual FY2025 figure was 0.71, 18.32% up from the prior year.
- Equity Ratio reached 0.71 in Q1 2025 per SXTC's latest filing, up from 0.6 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.71 in Q1 2025 and bottomed at 0.46 in Q1 2021.
- Average Equity Ratio over 5 years is 0.55, with a median of 0.5 recorded in 2023.
- Peak YoY movement for Equity Ratio: rose 3.69% in 2023, then rose 21.17% in 2024.
- A 5-year view of Equity Ratio shows it stood at 0.46 in 2021, then grew by 3.77% to 0.48 in 2022, then grew by 3.69% to 0.5 in 2023, then grew by 21.17% to 0.6 in 2024, then rose by 18.32% to 0.71 in 2025.
- Per Business Quant database, its latest 3 readings for Equity Ratio were 0.71 in Q1 2025, 0.6 in Q1 2024, and 0.5 in Q1 2023.